Committed to responsible pain management
Developing innovative and differentiated products for people suffering from pain
At Collegium Pharmaceutical we are committed to being the leader in responsible pain management. We have developed a portfolio of meaningfully differentiated products for use in the treatment of moderate to severe pain.
News and Press
Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020Read More November 05, 2020
Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain MedicineRead More October 26, 2020